Skip to content
PubMed This is a summary of 10 peer-reviewed journal articles Updated
Nephrology

What Blood Pressure Goals Are Recommended for ADPKD?

At a Glance

For adults under 50 with early ADPKD and well-preserved kidney function, a standardized office blood pressure target of ≤110/75 mmHg may be recommended if tolerated safely. Older adults and people with more advanced disease usually need an individualized systolic goal, often below 120 mmHg.

It is very common for people with Autosomal Dominant Polycystic Kidney Disease (ADPKD) to wonder why their doctor might aim for a blood pressure target that is significantly lower than the standard 120/80 mmHg reference value. For a specific group of patients—generally adults under the age of 50 with early-stage ADPKD and well-preserved kidney function—current guidelines recommend a standardized office blood pressure target of ≤ 110/75 mmHg, but only when it can be safely tolerated [1][2].

For older adults, or those with more advanced disease, guidelines generally recommend a systolic target (the top number) of < 120 mmHg [1]. However, these are not universal rules; targets must always be individualized based on your age, other health conditions, and how well you tolerate the medications [1][3].

The HALT-PKD Trial and Kidney Size

Much of the evidence for lower blood pressure targets in early ADPKD comes from a major study called the HALT-PKD trial. This trial looked specifically at patients under 50 with preserved kidney function to see if an intensive target (approximately 95/60 to 110/75 mmHg) offered more benefit than a standard target (120/70 to 130/80 mmHg) [4][3].

The study showed that intensive blood pressure control modestly slowed the physical enlargement of the kidneys [4]. Patients in the intensive target group saw their Total Kidney Volume (TKV)—a measurement of kidney enlargement used to track disease progression—grow about 14% slower than those with standard blood pressure targets [4][5]. Intensive control also reduced the strain on the heart, leading to less enlargement of the heart muscle (left ventricular mass) [6].

The Role of Hemodynamic Strain and Hormones

As cysts expand in ADPKD, they can compress the surrounding healthy kidney tissue. This compression may restrict local blood flow and contribute to the activation of the renin-angiotensin-aldosterone system (RAAS), a hormonal pathway that raises systemic blood pressure [7][8].

Medications that block this pathway—such as ACE inhibitors or ARBs—are often used as first-line treatments to manage hypertension in ADPKD [9][1]. Lowering blood pressure reduces the hemodynamic strain (the physical pressure on the kidney’s blood vessels), which is believed to be one mechanism that helps slow cyst growth [4].

What About Kidney Function (eGFR)?

While the trial showed a structural benefit in slowing kidney enlargement, the strict blood pressure control did not significantly change the overall rate of kidney function decline over the trial period [4]. Kidney function is measured by eGFR (estimated glomerular filtration rate).

In fact, patients in the intensive group saw their eGFR drop a bit faster in the first four months, before stabilizing and declining marginally slower thereafter [4]. A small early dip in eGFR is common when starting medications like ACE inhibitors or ARBs, as it reflects a change in pressure inside the kidney rather than permanent damage. Clinicians closely monitor both TKV and eGFR over time because ADPKD is characterized by structural enlargement that can precede major drops in filtering function by many years [10].

Balancing Goals and Side Effects: Safety First

An intensive target of ≤ 110/75 mmHg is never meant to be achieved at the expense of your daily safety [1]. Some patients accustomed to higher blood pressure may experience orthostatic hypotension—a sudden drop in blood pressure when standing up that causes dizziness, lightheadedness, or tiredness.

If you feel dizzy or faint, sit or lie down immediately. Do not stop or change your medications without speaking to your care team.

Your doctor will likely want to monitor your blood work (checking kidney function and potassium levels) shortly after starting or adjusting blood pressure medications [1]. Importantly, ACE inhibitors and ARBs should not routinely be combined unless specifically directed by a specialist, as doing so can increase the risk of side effects like high potassium or acute kidney injury.

Monitoring at Home

Measuring your blood pressure correctly at home helps your doctor know if you are safely reaching your goals. When checking your blood pressure:

  • Use a validated arm cuff.
  • Rest quietly for 5 minutes before checking.
  • Sit with your feet flat on the floor and your arm supported at heart level.
  • Keep a log of your numbers, the time of day, and any symptoms you experience.
  • Discuss with your doctor what specific home readings, or symptoms like persistent dizziness, should prompt a call to the clinic.

Common questions in this guide

What blood pressure target may be used for younger people with early ADPKD?
For adults younger than 50 who have early ADPKD and well-preserved kidney function, guidelines may recommend a standardized office blood pressure target of ≤110/75 mmHg when it can be tolerated safely. This lower target should be set and monitored by the treating clinician.
Is a blood pressure goal of 110/75 right for everyone with ADPKD?
No. Older adults and people with more advanced disease are generally managed with a systolic, or top-number, goal below 120 mmHg, but the right target depends on age, kidney function, other health conditions, medicines, and symptoms.
Can tighter blood pressure control slow kidney enlargement in ADPKD?
In the HALT-PKD trial, intensive blood pressure control modestly slowed growth in total kidney volume by about 14% and reduced enlargement of the heart muscle. It did not significantly change the overall rate of kidney function decline during the trial.
What should I do if I become dizzy or faint after standing?
Sit or lie down immediately and tell your care team about the symptom. Do not stop or change your blood pressure medicine on your own; your clinician can decide whether the target or dose needs adjustment.
How are ACE inhibitors and ARBs monitored in ADPKD?
ACE inhibitors and ARBs are commonly used to treat high blood pressure in ADPKD. Clinicians usually check kidney function and potassium soon after starting or changing one, and these medicines should not routinely be combined unless a specialist specifically directs it.
How should I measure my blood pressure at home?
Use a validated upper-arm cuff, rest quietly for five minutes, and sit with your feet flat and arm supported at heart level. Record the readings, time, and symptoms, and ask your care team which numbers or symptoms should prompt a call.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Based on my age, current kidney function (eGFR), and overall health, is an intensive blood pressure target appropriate for me, or should we aim for a different personalized goal?
  2. 2.If I experience dizziness or lightheadedness when standing up, what is our action plan for safely adjusting my medications?
  3. 3.Which blood pressure medication (such as an ACE inhibitor or ARB) is best for me, and when will we check my potassium and kidney function after starting it?
  4. 4.What are my specific thresholds for home blood pressure readings, and what numbers should prompt me to call the clinic?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (10)
  1. 1

    New insights in the pathophysiology and treatment of hypertension in autosomal dominant polycystic kidney disease.

    Dumont A, Bellien J, Van Wynsberghe M, et al.

    Kidney international 2025; (108(4)):592-608 doi:10.1016/j.kint.2025.05.036.

    PMID: 40712885
  2. 2

    Autosomal Dominant Polycystic Kidney Disease: Core Curriculum 2025.

    Gordon CE, Garimella PS, Perrone RD, Miskulin DC

    American journal of kidney diseases : the official journal of the National Kidney Foundation 2025; (86(4)):525-542 doi:10.1053/j.ajkd.2025.05.010.

    PMID: 40844441
  3. 3

    Treatment of Autosomal-Dominant Polycystic Kidney Disease.

    Jdiaa SS, Mustafa RA, Yu ASL

    American journal of kidney diseases : the official journal of the National Kidney Foundation 2025; (85(4)):491-500 doi:10.1053/j.ajkd.2024.08.008.

    PMID: 39424253
  4. 4

    Prognostic enrichment design in clinical trials for autosomal dominant polycystic kidney disease: the HALT-PKD clinical trial.

    Irazabal MV, Abebe KZ, Bae KT, et al.

    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 2017; (32(11)):1857-1865 doi:10.1093/ndt/gfw294.

    PMID: 27484667
  5. 5

    Determinants of Progression in Early Autosomal Dominant Polycystic Kidney Disease: Is it Blood Pressure or Renin-Angiotensin-Aldosterone-System Blockade?

    Brosnahan GM, Abebe KZ, Moore CG, et al.

    Current hypertension reviews 2018; (14(1)):39-47 doi:10.2174/1573402114666180322110209.

    PMID: 29564978
  6. 6

    Longitudinal Assessment of Left Ventricular Mass in Autosomal Dominant Polycystic Kidney Disease.

    Dad T, Abebe KZ, Bae KT, et al.

    Kidney international reports 2018; (3(3)):619-624 doi:10.1016/j.ekir.2017.12.011.

    PMID: 29854969
  7. 7

    Urinary renin-angiotensin markers in polycystic kidney disease.

    Salih M, Bovée DM, Roksnoer LCW, et al.

    American journal of physiology. Renal physiology 2017; (313(4)):F874-F881 doi:10.1152/ajprenal.00209.2017.

    PMID: 28747358
  8. 8

    Increased urinary Angiotensinogen/Creatinine (AGT/Cr) ratio may be associated with reduced renal function in autosomal dominant polycystic kidney disease patients.

    Park HC, Kang AY, Jang JY, et al.

    BMC nephrology 2015; (16()):86 doi:10.1186/s12882-015-0075-8.

    PMID: 26092580
  9. 9

    Update on pathogenesis, management, and treatment of hypertension in autosomal dominant polycystic kidney disease.

    Helal I, Al-Rowaie F, Abderrahim E, Kheder A

    Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia 2017; (28(2)):253-260 doi:10.4103/1319-2442.202774.

    PMID: 28352004
  10. 10

    Long-term trajectory of kidney function in autosomal-dominant polycystic kidney disease.

    Yu ASL, Shen C, Landsittel DP, et al.

    Kidney international 2019; (95(5)):1253-1261 doi:10.1016/j.kint.2018.12.023.

    PMID: 30922668

This page explains blood pressure targets in ADPKD for informational purposes only and does not constitute medical advice. Your nephrologist or care team should set and adjust your goal based on your readings, kidney function, symptoms, and overall health.

Get notified when new evidence is published on Autosomal dominant polycystic kidney disease.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.